Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease

Molecular Brain

Volumn 2, Issue 1, 2009, Pages

  Pineda, Jose R ^a,b   Pardo, Ral ^a,b   Zala, Diana ^a,b   Yu, Hua ^a,b   Humbert, Sandrine ^a,b   Saudou, Frédéric ^a,b  

^a INSTITUT D'OPTIQUE GRADUATE SCHOOL   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCINEURIN; HUNTINGTIN; SERINE; TACROLIMUS; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE; PHOSPHOSERINE; POLYGLUTAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL DEATH; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUNTINGTON CHOREA; MOUSE; NERVE CELL MEMBRANE; NERVE FIBER TRANSPORT; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; ANIMAL; BRAIN CORTEX; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; RAT; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL;

MUS; RATTUS;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCINEURIN; CEREBRAL CORTEX; HUNTINGTON DISEASE; MICE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; PHOSPHORYLATION; PHOSPHOSERINE; RATS; RNA INTERFERENCE; TACROLIMUS;

EID: 72949098095     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-2-33     Document Type: Article

References (50)

1. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. M Borrell-Pages D Zala S Humbert F Saudou, Cell Mol Life Sci 2006 63 2642 2660 10.1007/s00018-006-6242-0 17041811
2. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. E Roze F Saudou J Caboche, Curr Opin Neurol 2008 21 497 503 10.1097/WCO.0b013e328304b692 18607213
3. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. LR Gauthier BC Charrin M Borrell-Pages JP Dompierre H Rangone FP Cordelieres J De Mey ME MacDonald V Lessmann S Humbert F Saudou, Cell 2004 118 127 138 10.1016/j.cell.2004.06.018 15242649
4. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. S Gunawardena LS Her RG Brusch RA Laymon IR Niesman B Gordesky-Gold L Sintasath NM Bonini LS Goldstein, Neuron 2003 40 25 40 10.1016/S0896-6273(03)00594-4 14527431
5. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. WC Lee M Yoshihara JT Littleton, Proc Natl Acad Sci USA 2004 101 3224 3229 10.1073/pnas.0400243101 14978262
6. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. G Szebenyi GA Morfini A Babcock M Gould K Selkoe DL Stenoien M Young PW Faber ME MacDonald MJ McPhaul ST Brady, Neuron 2003 40 41 52 10.1016/S0896-6273(03)00569-5 14527432
7. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. E Trushina RB Dyer JD Badger 2nd D Ure L Eide DD Tran BT Vrieze V Legendre-Guillemin PS McPherson BS Mandavilli, et al. Mol Cell Biol 2004 24 8195 8209 10.1128/MCB.24.18.8195-8209.2004 15340079
8. Interaction of huntingtin-associated protein with dynactin P150Glued. SH Li CA Gutekunst SM Hersch XJ Li, J Neurosci 1998 18 1261 1269 9454836
9. Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. S Engelender AH Sharp V Colomer MK Tokito A Lanahan P Worley EL Holzbaur CA Ross, Hum Mol Genet 1997 6 2205 2212 10.1093/hmg/6.13.2205 9361024
10. Huntingtin facilitates dynein/dynactin-mediated vesicle transport. JP Caviston JL Ross SM Antony M Tokito EL Holzbaur, Proc Natl Acad Sci USA 2007 104 10045 10050 10.1073/pnas.0610628104 17548833
11. Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. JR McGuire J Rong SH Li XJ Li, J Biol Chem 2006 281 3552 3559 10.1074/jbc.M509806200 16339760
12. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. E Colin D Zala G Liot H Rangone M Borrell-Pages XJ Li F Saudou S Humbert, Embo J 2008 27 2124 2134 10.1038/emboj.2008.133 18615096
13. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. D Zala E Colin H Rangone G Liot S Humbert F Saudou, Hum Mol Genet 2008 17 24 3837 46 10.1093/hmg/ddn281 18772195
14. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. S Humbert EA Bryson FP Cordelieres NC Connors SR Datta S Finkbeiner ME Greenberg F Saudou, Dev Cell 2002 2 831 837 10.1016/S1534-5807(02)00188-0 12062094
15. Inhibition of calcineurin by FK506 protects against polyglutamine- huntingtin toxicity through an increase of huntingtin phosphorylation at S421. R Pardo E Colin E Regulier P Aebischer N Deglon S Humbert F Saudou, J Neurosci 2006 26 1635 1645 10.1523/JNEUROSCI.3706-05.2006 16452687
16. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. D Zala JC Bensadoun L Pereira de Almeida BR Leavitt CA Gutekunst P Aebischer MR Hayden N Deglon, Exp Neurol 2004 185 26 35 10.1016/j.expneurol.2003.09.002 14697316
17. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. SC Warby EY Chan M Metzler L Gan RR Singaraja SF Crocker HA Robertson MR Hayden, Hum Mol Genet 2005 14 1569 1577 10.1093/hmg/ddi165 15843398
18. Akt is altered in an animal model of Huntington's disease and in patients. E Colin E Regulier V Perrin A Durr A Brice P Aebischer N Deglon S Humbert F Saudou, Eur J Neurosci 2005 21 1478 1488 10.1111/j.1460-9568.2005. 03985.x 15845076
19. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. X Xifro JM Garcia-Martinez D Del Toro J Alberch E Perez-Navarro, J Neurochem 2008 105 1596 1612 10.1111/j.1471-4159.2008.05252.x 18221365
20. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro. G Ermak KJ Hench KT Chang S Sachdev KJ Davies, J Biol Chem 2009 284 11845 11853 10.1074/jbc. M900639200 19270310
21. Comparative study of the distribution of calmodulin kinase II and calcineurin in the mouse brain. C Sola JM Tusell J Serratosa, J Neurosci Res 1999 57 651 662 10.1002/(SICI)1097-4547(19990901)57:5<651::AID-JNR7>3.0. CO;2-G 10462689
22. Calcineurin: form and function. F Rusnak P Mertz, Physiol Rev 2000 80 1483 1521 11015619
23. Calcineurin as a multifunctional regulator. F Shibasaki U Hallin H Uchino, J Biochem 2002 131 1 15 11754729
24. Calcineurin: a central controller of signalling in eukaryotes. J Aramburu J Heitman GR Crabtree, EMBO Rep 2004 5 343 348 10.1038/sj.embor.7400133 15060569
25. The role of modulatory calcineurin-interacting proteins in calcineurin signaling. BA Rothermel RB Vega RS Williams, Trends Cardiovasc Med 2003 13 15 21 10.1016/S1050-1738(02)00188-3 12554096
26. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. B Rothermel RB Vega J Yang H Wu R Bassel-Duby RS Williams, J Biol Chem 2000 275 8719 8725 10.1074/jbc.275.12.8719 10722714
27. Novel human ZAKI-4 isoforms: hormonal and tissue-specific regulation and function as calcineurin inhibitors. X Cao F Kambe T Miyazaki D Sarkar S Ohmori H Seo, Biochem J 2002 367 459 466 10.1042/BJ20011797 12102656
28. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. J Gorlach DS Fox NS Cutler GM Cox JR Perfect J Heitman, EMBO J 2000 19 3618 3629 10.1093/emboj/19.14.3618 10899116
29. A conserved family of calcineurin regulators. TJ Kingsbury KW Cunningham, Genes Dev 2000 14 1595 1604 10887154
30. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. JJ Fuentes L Genesca TJ Kingsbury KW Cunningham M Perez-Riba X Estivill S de la Luna, Hum Mol Genet 2000 9 1681 1690 10.1093/hmg/9.11.1681 10861295
31. FK506 and its analogs - therapeutic potential for neurological disorders. A Klettner T Herdegen, Curr Drug Targets CNS Neurol Disord 2003 2 153 162 10.2174/1568007033482878 12769796
32. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. K Pong MM Zaleska, Curr Drug Targets CNS Neurol Disord 2003 2 349 356 10.2174/1568007033482652 14683462
33. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. JP Dompierre JD Godin BC Charrin FP Cordelieres SJ King S Humbert F Saudou, J Neurosci 2007 27 3571 3583 10.1523/JNEUROSCI.0037-07.2007 17392473
34. Protein serine/threonine phosphatases - new avenues for cell regulation. S Shenolikar, Annu Rev Cell Biol 1994 10 55 86 10.1146/annurev.cb.10.110194. 000415 7888183
35. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. CA Altar N Cai T Bliven M Juhasz JM Conner AL Acheson RM Lindsay SJ Wiegand, Nature 1997 389 856 860 10.1038/39885 9349818
36. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. ZC Baquet JA Gorski KR Jones, J Neurosci 2004 24 4250 4258 10.1523/JNEUROSCI.3920- 03.2004 15115821
37. Neuropathological classification of Huntington's disease. JP Vonsattel RH Myers TJ Stevens RJ Ferrante ED Bird EP Richardson Jr, Journal of Neuropathology & Experimental Neurology 1985 44 559 577 10.1097/00005072- 198511000-00003
38. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. JM Conner JC Lauterborn Q Yan CM Gall S Varon, J Neurosci 1997 17 2295 2313 9065491
39. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. JR Pineda JM Canals M Bosch A Adell G Mengod F Artigas P Ernfors J Alberch, J Neurochem 2005 93 1057 1068 10.1111/j.1471-4159.2005.03047.x 15934928
40. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. VC Wheeler CA Gutekunst V Vrbanac LA Lebel G Schilling S Hersch RM Friedlander JF Gusella JP Vonsattel DR Borchelt ME MacDonald, Hum Mol Genet 2002 11 633 640 10.1093/hmg/11.6.633 11912178
41. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. J Sharkey SP Butcher, Nature 1994 371 336 339 10.1038/371336a0 7522303
42. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. H Uchino R Minamikawa-Tachino T Kristian G Perkins M Narazaki BK Siesjo F Shibasaki, Neurobiol Dis 2002 10 219 233 10.1006/nbdi.2002.0514 12270685
43. Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia. K Miyata N Omori H Uchino T Yamaguchi A Isshiki F Shibasaki, Neuroscience 2001 105 571 578 10.1016/S0306-4522(01)00225-1 11516824
44. Calcium signaling and neurodegenerative diseases. I Bezprozvanny, Trends Mol Med 2009 15 89 100 10.1016/j.molmed.2009.01.001 19230774
45. Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death. MJ Kim DG Jo GS Hong BJ Kim M Lai DH Cho KW Kim A Bandyopadhyay YM Hong H Kim do, et al. Proc Natl Acad Sci USA 2002 99 9870 9875 12114545 10.1073/pnas.152336999 (Pubitemid 34831139)
46. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. N Bizat JM Hermel F Boyer C Jacquard C Creminon S Ouary C Escartin P Hantraye S Kajewski E Brouillet, J Neurosci 2003 23 5020 5030 12832525
47. Calpain activation in Huntington's disease. J Gafni LM Ellerby, J Neurosci 2002 22 4842 4849 12077181
48. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. F Saudou S Finkbeiner D Devys ME Greenberg, Cell 1998 95 55 66 10.1016/S0092-8674(00)81782-1 9778247
49. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Y Trottier D Devys G Imbert F Saudou I An Y Lutz C Weber Y Agid EC Hirsch JL Mandel, Nat Genet 1995 10 104 110 10.1038/ng0595-104 7647777
50. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock- in mice. VC Wheeler JK White CA Gutekunst V Vrbanac M Weaver XJ Li SH Li H Yi JP Vonsattel JF Gusella, et al. Hum Mol Genet 2000 9 503 513 10.1093/hmg/9.4.503 10699173